Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
酪氨酸激酶
肿瘤科
突变
作者
Vivek Subbiah,Tao Shen,Michael T. Tetzlaff,Annikka Weissferdt,Lauren Averett Byers,Tina Cascone,Amini Behrang,Funda Meric-Bernstam,Blaine H. M. Mooers,Stephen M. Rothenberg,Kevin Ebata,Jie Wu